PARP inhibitors for anticancer therapy

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

(2013) Ruth Plummer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond

(2013) Nicola J. Curtin et al.   MOLECULAR ASPECTS OF MEDICINE

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

CS1-Directed Monoclonal Antibody Therapy for Multiple Myeloma

(2012) Don M. Benson et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased PARP-1 Association with DNA in Alkylation Damaged, PARP-Inhibited Mouse Fibroblasts

(2012) P. S. Kedar et al.   MOLECULAR CANCER RESEARCH

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

(2011) O A Khan et al.   BRITISH JOURNAL OF CANCER

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

(2011) S. Kummar et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

(2011) Jonathan A. Ledermann et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Development of Vascular Disrupting Agents: What Lessons Can We Learn From ASA404?

(2011) Patricia M. LoRusso et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy

(2011) M. Javle et al.   Therapeutic Advances in Medical Oncology

Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target

(2010) R. Plummer   CLINICAL CANCER RESEARCH

How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation

(2010) Aswin Mangerich et al.   INTERNATIONAL JOURNAL OF CANCER

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic

(2010) Dana V. Ferraris   JOURNAL OF MEDICINAL CHEMISTRY

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

(2010) Yvette Drew et al.   JNCI-Journal of the National Cancer Institute

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma

(2009) Agop Y. Bedikian et al.   CANCER INVESTIGATION

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

(2008) B. Evers et al.   CLINICAL CANCER RESEARCH